Optimizing coordinated reset deep brain stimulation for Parkinson's disease
优化帕金森病的协调重置深部脑刺激
基本信息
- 批准号:10636865
- 负责人:
- 金额:$ 62.56万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2020
- 资助国家:美国
- 起止时间:2020-09-30 至 2025-06-30
- 项目状态:未结题
- 来源:
- 关键词:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridineAcuteAdvanced DevelopmentAdverse effectsAffectAnimalsAreaBasal GangliaBehavioralBiological MarkersBrainClinicalClinical ResearchConsumptionDataDeep Brain StimulationDevelopmentDorsalEffectivenessEnergy consumptionEvaluationExperimental DesignsFrequenciesFutureGlobus PallidusGoalsHealthcare SystemsHourImplantIncidenceLeadMeasuresModelingMotorMovementNeurodegenerative DisordersNeuronsNodalOperative Surgical ProceduresOutcomeParkinson DiseaseParkinsonian DisordersPatient CarePatientsPatternPersonsPrefrontal CortexProbabilityQuality of lifeResearchRestSiteStructureStructure of subthalamic nucleusTestingTherapeuticTherapeutic EffectTimeTranslationsUtahWorkbattery lifebattery rechargingdeep brain stimulation arraydensityeffective therapyhuman subjectimprovedmotor disordermotor function improvementmotor symptomneuralneurotransmissionnonhuman primatenovelnovel strategiespreclinical studyside effectspecific biomarkerstherapeutically effectivetranslational therapeutics
项目摘要
PROJECT SUMMARY/ABSTRACT
Parkinson’s disease (PD) is a neurodegenerative disorder affecting 6-7 million people worldwide. Traditional
high frequency, isochronal deep brain stimulation (DBS) is an effective treatment for the motor signs associated
with PD. Clinical outcomes, however, vary across centers and within centers across patients. Adverse effects
can be induced by “current-spread” to unintended brain areas when the DBS lead is sub-optimally placed which
limits clinical benefits. Coordinated reset (CR) DBS is a promising novel DBS approach that has the potential to
overcome the limitations of traditional DBS. By alternating lower intensity stimulation delivered in a burst pattern
across different contacts of the DBS lead, CR DBS is associated with less current spread, thus reducing the
incidence of adverse effects, and improvement in motor signs that persist for days to weeks after cessation of
stimulation, i.e. carryover effect. Although the effectiveness of CR DBS has been demonstrated in both preclinical
and clinical studies, the selection of CR parameters that provide the greatest carryover effect has been
challenging. The optimal target for CR DBS must also be identified. The proposed study using a within-subject
experimental design will 1) optimize the critical parameter (cycle rate) of CR DBS, (2) compare the effect of CR
DBS in the subthalamic nucleus (STN) and internal segment of the globus pallidus (GPi), and (3) characterize
the changes in cortical and subcortical neuronal activities associated with its therapeutic effect. The nonhuman
primate model of PD will be used with each animal implanted with DBS leads in the STN and GPi and high-
density Utah arrays placed over the primary motor, dorsal premotor and dorsolateral prefrontal cortices.
Objective and quantitative motor assessments will be performed to measure the acute and carryover effect of
CR DBS with different cycle rates and in different targets (STN and GPi). The central hypothesis is that the
therapeutic effect of CR DBS is greatest when the cycle rate is based on subject-specific pathophysiological
biomarkers associated with the PD state. We further hypothesize that CR DBS in GPi will provide greater acute
benefits in motor signs and induce significantly longer carryover effects. We predict that motor improvements
induced by CR DBS will correlate with a reduction in synchronized neuronal activity within and across cortical
and subcortical nodal points in the basal-ganglia-thalamocortical (BGTC) circuit. The results of this study will
provide a time efficient approach for the selection of CR DBS cycle rate based on subject-specific biomarker
activity in the BGTC circuit, identify the optimal target for CR DBS and enhance our understanding of the
mechanism(s) underlying the therapeutic effect of CR DBS. Results of the study will significantly advance the
development of CR DBS for the treatment of PD that will enhance clinical outcomes, prolong battery life and
induce fewer side effects leading to higher quality of life for PD patients undergoing DBS.
项目概要/摘要
帕金森病 (PD) 是一种神经退行性疾病,影响全球 6-700 万人。
高频等时深部脑刺激 (DBS) 是治疗相关运动症状的有效方法
然而,PD 的临床结果因中心和中心内患者的不良反应而异。
当 DBS 导线放置得不理想时,可能会因“电流扩散”到非预期的大脑区域而引起
协调复位 (CR) DBS 是一种有前景的新型 DBS 方法,有潜力
通过以突发模式交替提供较低强度的刺激,克服了传统 DBS 的局限性。
在 DBS 引线的不同触点上,CR DBS 与较小的电流分布相关,从而减少了
不良反应的发生率以及停止后持续数天至数周的运动体征的改善
尽管 CR DBS 的有效性已在临床前得到证实。
和临床研究中,提供最大残留效应的 CR 参数的选择已被
还必须确定使用受试者内部的拟议研究的最佳目标。
实验设计将1)优化CR DBS的关键参数(循环率),(2)比较CR的效果
丘脑底核 (STN) 和苍白球内段 (GPi) 中的 DBS,以及 (3) 表征
与其治疗效果相关的皮质和皮质下神经活动的变化。
将使用 PD 灵长类动物模型,每只动物在 STN 和 GPi 中植入 DBS 导线,并且高
密度犹他阵列放置在初级运动、背侧前运动和背外侧前额叶皮质上。
将进行客观和定量的运动评估,以测量急性和残留效应
CR DBS 具有不同的循环率和不同的目标(STN 和 GPi)。
当循环率基于受试者特定的病理生理学时,CR DBS 的治疗效果最佳
我们进一步发现 GPi 中的 CR DBS 将提供更大的急性度。
我们预测,运动症状会得到改善,并会产生明显更长的残留效应。
CR DBS 引起的脑电波与皮层内部和皮层间同步神经活动的减少相关
本研究的结果将包括基底神经节丘脑皮质 (BGTC) 回路中的皮质下节点和皮质下节点。
提供一种基于受试者特定生物标志物选择 CR DBS 循环速率的省时方法
BGTC 回路中的活动,确定 CR DBS 的最佳目标并增强我们对
CR DBS 治疗效果的机制将显着推进。
开发用于治疗 PD 的 CR DBS,将提高临床结果、延长电池寿命和
引起较少的副作用,从而提高接受 DBS 的 PD 患者的生活质量。
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Effect of subthalamic coordinated reset deep brain stimulation on Parkinsonian gait.
- DOI:10.3389/fninf.2023.1185723
- 发表时间:2023
- 期刊:
- 影响因子:3.5
- 作者:Bosley, Kai M.;Luo, Ziling;Amoozegar, Sana;Acedillo, Kit;Nakajima, Kanon;Johnson, Luke A.;Vitek, Jerrold L.;Wang, Jing
- 通讯作者:Wang, Jing
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jing Wang其他文献
Electrochemical performance of high-capacity nanostructured Li[Li0.2Mn0.54Ni0.13Co0.13]O2 cathode material for lithium ion battery by hydrothermal method
水热法制备锂离子电池高容量纳米结构Li[Li0.2Mn0.54Ni0.13Co0.13]O2正极材料的电化学性能
- DOI:
10.1016/j.electacta.2013.05.118 - 发表时间:
2013-09 - 期刊:
- 影响因子:6.6
- 作者:
Xin Wei;Shichao Zhang;Zhijia Du;Puheng Yang;Jing Wang;Yanbiao Ren - 通讯作者:
Yanbiao Ren
Jing Wang的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jing Wang', 18)}}的其他基金
Targeting Sigma 1 receptor as a novel therapy for limiting neurovascular injury in ROP
靶向 Sigma 1 受体作为限制 ROP 神经血管损伤的新疗法
- 批准号:
10718424 - 财政年份:2023
- 资助金额:
$ 62.56万 - 项目类别:
Optimizing coordinated reset deep brain stimulation for Parkinson's disease
优化帕金森病的协调重置深部脑刺激
- 批准号:
10267675 - 财政年份:2020
- 资助金额:
$ 62.56万 - 项目类别:
Optimizing coordinated reset deep brain stimulation for Parkinson's disease
优化帕金森病的协调重置深部脑刺激
- 批准号:
10413216 - 财政年份:2020
- 资助金额:
$ 62.56万 - 项目类别:
Optimizing coordinated reset deep brain stimulation for Parkinson's disease
优化帕金森病的协调重置深部脑刺激
- 批准号:
10030344 - 财政年份:2020
- 资助金额:
$ 62.56万 - 项目类别:
Targeting TGFbeta/PDK4 to Overcome Drug Resistance in Colorectal Cancer
靶向 TGFbeta/PDK4 克服结直肠癌耐药性
- 批准号:
10000912 - 财政年份:2018
- 资助金额:
$ 62.56万 - 项目类别:
相似国自然基金
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
- 批准号:82300697
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
Tenascin-X对急性肾损伤血管内皮细胞的保护作用及机制研究
- 批准号:82300764
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
ACSS2介导的乙酰辅酶a合成在巨噬细胞组蛋白乙酰化及急性肺损伤发病中的作用机制研究
- 批准号:82370084
- 批准年份:2023
- 资助金额:48 万元
- 项目类别:面上项目
KIF5B调控隧道纳米管介导的线粒体转运对FLT3-ITD阳性急性髓系白血病的作用机制
- 批准号:82370175
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
PHF6突变通过相分离调控YTHDC2-m6A-SREBP2信号轴促进急性T淋巴细胞白血病发生发展的机制研究
- 批准号:82370165
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Optimizing coordinated reset deep brain stimulation for Parkinson's disease
优化帕金森病的协调重置深部脑刺激
- 批准号:
10267675 - 财政年份:2020
- 资助金额:
$ 62.56万 - 项目类别:
Optimizing coordinated reset deep brain stimulation for Parkinson's disease
优化帕金森病的协调重置深部脑刺激
- 批准号:
10413216 - 财政年份:2020
- 资助金额:
$ 62.56万 - 项目类别:
Optimizing coordinated reset deep brain stimulation for Parkinson's disease
优化帕金森病的协调重置深部脑刺激
- 批准号:
10030344 - 财政年份:2020
- 资助金额:
$ 62.56万 - 项目类别:
Neuronal Activity in MC and SMA during STN and GPi DBS in the Parkinsonian Monkey
帕金森猴 STN 和 GPi DBS 期间 MC 和 SMA 的神经元活动
- 批准号:
8392418 - 财政年份:2012
- 资助金额:
$ 62.56万 - 项目类别:
Neuronal Activity in MC and SMA during STN and GPi DBS in the Parkinsonian Monkey
帕金森猴 STN 和 GPi DBS 期间 MC 和 SMA 的神经元活动
- 批准号:
9103227 - 财政年份:2012
- 资助金额:
$ 62.56万 - 项目类别: